Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial
PURPOSE - - With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory mult...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 04, 2023
|
| In: |
Journal of clinical oncology
Year: 2023, Jahrgang: 41, Heft: 8, Pages: 1590-1599 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.22.00940 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.22.00940 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.22.00940 
|
| Verfasserangaben: | Meletios A. Dimopoulos, MD; Albert Oriol, MD; Hareth Nahi, MD, PhD; Jesus San-Miguel, MD, PhD ; Nizar J. Bahlis, MD; Saad Z. Usmani, MD, MBA; Neil Rabin, MBBS, PhD; Robert Z. Orlowski, MD, PhD; Kenshi Suzuki, MD, PhD; Torben Plesner, MD; Sung-Soo Yoon, MD, PhD; Dina Ben Yehuda, MD; Paul G. Richardson, MD; Hartmut Goldschmidt, MD; Donna Reece, MD; Tahamtan Ahmadi, MD, PhD; Xiang Qin, MS; Wendy Garvin Mayo, APRN, ANP-BC, MSN; Lue Gai, MMed; Jodi Carey, BSN; Robin Carson, MD; and Philippe Moreau, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1858649757 | ||
| 003 | DE-627 | ||
| 005 | 20240307054908.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230904s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.00940 |2 doi | |
| 035 | |a (DE-627)1858649757 | ||
| 035 | |a (DE-599)KXP1858649757 | ||
| 035 | |a (OCoLC)1425212219 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dimopoulos, Meletios A. |e VerfasserIn |0 (DE-588)111795188X |0 (DE-627)871747634 |0 (DE-576)479413746 |4 aut | |
| 245 | 1 | 0 | |a Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX) |b a randomized, open-label, phase III trial |c Meletios A. Dimopoulos, MD; Albert Oriol, MD; Hareth Nahi, MD, PhD; Jesus San-Miguel, MD, PhD ; Nizar J. Bahlis, MD; Saad Z. Usmani, MD, MBA; Neil Rabin, MBBS, PhD; Robert Z. Orlowski, MD, PhD; Kenshi Suzuki, MD, PhD; Torben Plesner, MD; Sung-Soo Yoon, MD, PhD; Dina Ben Yehuda, MD; Paul G. Richardson, MD; Hartmut Goldschmidt, MD; Donna Reece, MD; Tahamtan Ahmadi, MD, PhD; Xiang Qin, MS; Wendy Garvin Mayo, APRN, ANP-BC, MSN; Lue Gai, MMed; Jodi Carey, BSN; Robin Carson, MD; and Philippe Moreau, MD |
| 264 | 1 | |c January 04, 2023 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.09.2023 | ||
| 520 | |a PURPOSE - - With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the time of final analysis for overall survival (OS). - - METHODS - - POLLUX was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned 1:1 to D-Rd or Rd until disease progression or unacceptable toxicity. After positive primary analysis and protocol amendment, patients receiving Rd were offered daratumumab monotherapy after disease progression. - - RESULTS - - Significant OS benefit was observed with D-Rd (hazard ratio, 0.73; 95% CI, 0.58 to 0.91; P = .0044) at a median (range) follow-up of 79.7 months (0.0-86.5). The median OS was 67.6 months for D-Rd compared with 51.8 months for Rd. Prespecified analyses demonstrated an improved OS with D-Rd versus Rd in most subgroups, including patients age ≥ 65 years and patients with one, two, or three prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and refractoriness to their last prior line of therapy or a proteasome inhibitor. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Rd versus Rd were neutropenia (57.6% v 41.6%), anemia (19.8% v 22.4%), pneumonia (17.3% v 11.0%), thrombocytopenia (15.5% v 15.7%), and diarrhea (10.2% v 3.9%). - - CONCLUSION - - D-Rd significantly extended OS versus Rd alone in patients with RRMM. To our knowledge, for the first time, our findings, together with the OS benefit observed with daratumumab plus bortezomib and dexamethasone in the phase III CASTOR trial, demonstrate OS improvement with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02076009 [POLLUX]). | ||
| 700 | 1 | |a Oriol, Albert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nahi, Hareth |e VerfasserIn |4 aut | |
| 700 | 1 | |a San-Miguel, Jesus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bahlis, Nizar J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Usmani, Saad Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rabin, Neil |e VerfasserIn |4 aut | |
| 700 | 1 | |a Orlowski, Robert Z. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Suzuki, Kenshi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Plesner, Torben |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yoon, Sung-Soo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ben Yehuda, Dina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Richardson, Paul G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Reece, Donna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ahmadi, Tahamtan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Qin, Xiang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garvin Mayo, Wendy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gai, Xue |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carey, Jodi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carson, Robin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 41(2023), 8, Seite 1590-1599 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX) a randomized, open-label, phase III trial |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:8 |g pages:1590-1599 |g extent:13 |a Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX) a randomized, open-label, phase III trial |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.22.00940 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.22.00940 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230904 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 14 | ||
| 999 | |a KXP-PPN1858649757 |e 4372238037 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 04.09.2023"],"physDesc":[{"extent":"13 S."}],"relHost":[{"part":{"extent":"13","text":"41(2023), 8, Seite 1590-1599","volume":"41","issue":"8","pages":"1590-1599","year":"2023"},"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"subtitle":"JCO : an American Society of Clinical Oncology journal","title":"Journal of clinical oncology","title_sort":"Journal of clinical oncology"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"recId":"313116962","id":{"eki":["313116962"],"zdb":["2005181-5"],"issn":["1527-7755"]},"pubHistory":["1.1983 -"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"language":["eng"],"disp":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX) a randomized, open-label, phase III trialJournal of clinical oncology","corporate":[{"display":"American Society of Clinical Oncology","roleDisplay":"Herausgebendes Organ","role":"isb"}],"origin":[{"dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedKey":"1983"}]}],"language":["eng"],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"January 04, 2023"}],"person":[{"role":"aut","family":"Dimopoulos","given":"Meletios A.","roleDisplay":"VerfasserIn","display":"Dimopoulos, Meletios A."},{"role":"aut","family":"Oriol","given":"Albert","roleDisplay":"VerfasserIn","display":"Oriol, Albert"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Hareth","display":"Nahi, Hareth","family":"Nahi"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Jesus","display":"San-Miguel, Jesus","family":"San-Miguel"},{"family":"Bahlis","display":"Bahlis, Nizar J.","roleDisplay":"VerfasserIn","given":"Nizar J.","role":"aut"},{"family":"Usmani","roleDisplay":"VerfasserIn","display":"Usmani, Saad Z.","given":"Saad Z.","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Rabin, Neil","given":"Neil","family":"Rabin","role":"aut"},{"role":"aut","family":"Orlowski","roleDisplay":"VerfasserIn","display":"Orlowski, Robert Z.","given":"Robert Z."},{"family":"Suzuki","given":"Kenshi","roleDisplay":"VerfasserIn","display":"Suzuki, Kenshi","role":"aut"},{"family":"Plesner","roleDisplay":"VerfasserIn","display":"Plesner, Torben","given":"Torben","role":"aut"},{"roleDisplay":"VerfasserIn","given":"Sung-Soo","display":"Yoon, Sung-Soo","family":"Yoon","role":"aut"},{"role":"aut","family":"Ben Yehuda","roleDisplay":"VerfasserIn","display":"Ben Yehuda, Dina","given":"Dina"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Paul G.","display":"Richardson, Paul G.","family":"Richardson"},{"roleDisplay":"VerfasserIn","given":"Hartmut","display":"Goldschmidt, Hartmut","family":"Goldschmidt","role":"aut"},{"role":"aut","given":"Donna","roleDisplay":"VerfasserIn","display":"Reece, Donna","family":"Reece"},{"given":"Tahamtan","roleDisplay":"VerfasserIn","display":"Ahmadi, Tahamtan","family":"Ahmadi","role":"aut"},{"role":"aut","given":"Xiang","roleDisplay":"VerfasserIn","display":"Qin, Xiang","family":"Qin"},{"role":"aut","family":"Garvin Mayo","given":"Wendy","roleDisplay":"VerfasserIn","display":"Garvin Mayo, Wendy"},{"family":"Gai","given":"Xue","roleDisplay":"VerfasserIn","display":"Gai, Xue","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Jodi","display":"Carey, Jodi","family":"Carey"},{"role":"aut","given":"Robin","roleDisplay":"VerfasserIn","display":"Carson, Robin","family":"Carson"},{"role":"aut","family":"Moreau","display":"Moreau, Philippe","roleDisplay":"VerfasserIn","given":"Philippe"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"subtitle":"a randomized, open-label, phase III trial","title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX)","title_sort":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX)"}],"recId":"1858649757","id":{"eki":["1858649757"],"doi":["10.1200/JCO.22.00940"]},"name":{"displayForm":["Meletios A. Dimopoulos, MD; Albert Oriol, MD; Hareth Nahi, MD, PhD; Jesus San-Miguel, MD, PhD ; Nizar J. Bahlis, MD; Saad Z. Usmani, MD, MBA; Neil Rabin, MBBS, PhD; Robert Z. Orlowski, MD, PhD; Kenshi Suzuki, MD, PhD; Torben Plesner, MD; Sung-Soo Yoon, MD, PhD; Dina Ben Yehuda, MD; Paul G. Richardson, MD; Hartmut Goldschmidt, MD; Donna Reece, MD; Tahamtan Ahmadi, MD, PhD; Xiang Qin, MS; Wendy Garvin Mayo, APRN, ANP-BC, MSN; Lue Gai, MMed; Jodi Carey, BSN; Robin Carson, MD; and Philippe Moreau, MD"]}} | ||
| SRT | |a DIMOPOULOSOVERALLSUR0420 | ||